A five-day Alpine expedition study found that climbers who developed moderate-to-severe high-altitude headache showed significant rises in tear fluid CGRP, the neuropeptide central to migraine, ...

A Swiss real-world registry study found no recurrent ischemic events or new brain lesions among 17 migraine patients with ...

After being on a slew of non-migraine-specific medications without the benefits I expected, I felt frustrated and hopeless — until doing research for a neurobiology class in college. Here, I gave a ...

Vyepti (eptinezumab) is an anti-CGRP monoclonal antibody administered every 12 weeks via infusion for the prevention of episodic and chronic migraine attacks. Learn about its evidence, how to get it, ...

A statistically significant reduction in the mean number of monthly headache days (vs baseline) was observed for the CGRP-targeted therapies and propranolol ...

Lundbeck A/S , a biopharmaceutical company, announced positive results from the Phase IV THRIVE trial evaluating eptinezumab in adults with migraine who had an inadequate respo ...

Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...

In its first update since 2012, the American Academy of Neurology's new migraine treatment guidelines mean more people can ...

ORLANDO, Fla. — Use of calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine during early pregnancy was associated with an increased risk for miscarriage, results of a ...

Anti-calcitonin gene-related peptide monoclonal antibodies (mAbs) demonstrated meaningful and sustained effectiveness in reducing monthly migraine days (MMDs) across three consecutive 1-year treatment ...

Migraine is a commonly encountered condition, but it is a field that is surprisingly difficult to organize when actually providing care, including diagnostic criteria, how to use triptans, when to ...

Migraine patients taking CGRP inhibitors had a 25% lower risk of developing glaucoma within 3 years. Only monoclonal antibody CGRP inhibitors, not CGRP receptor antagonists, were linked with reduced ...